Search

Yin Liang

from Alexandria, VA
Age ~70
Get Report
Also known as:
Liang Yin, Yin Bai
Related to:
Eli E Liang, 61Natacha Z Liang, 55
Connected to:
Agnes Liang, 41Almon Liang, 81Amy Liang, 51Anderson Y Liang, 43Angela W Liang, 33Angelina A Liang, 29Anne W Liang, 59Arthur Z Liang, 40Carl Liang, 36Carly V Liang, 36

Yin Liang Phones & Addresses

  • Alexandria, VA
  • Three Bridges, NJ
  • 9855 Bayline Cir, Owings Mills, MD 21117 (410) 902-0976
  • Orlando, FL
  • Maple Glen, PA
  • Bridgewater, NJ
  • Bear, DE
  • Malden, MA
  • Newark, DE
  • McLean, VA
  • 715 Lawrence Ln, Ambler, PA 19002 (908) 429-1094

Work

Position: Executive, Administrative, and Managerial Occupations

Education

Degree: High school graduate or higher

Professional Records

License Records

Yin Zhi Liang

License #:
000450
Category:
Clinical Laboratory Technologist
Issued Date:
Oct 5, 2006
Type:
CLINICAL LABORATORY TECHNOLOGIST

Business Records

Name / Title
Company / Classification
Phones & Addresses
Yin Liang
Principal
Laings Carolina 7 LLC
Business Services at Non-Commercial Site
9855 Bayline Cir, Garrison, MD 21117

Publications

Us Patents

Method For Producing Pseudo Islets

View page
US Patent:
20040005299, Jan 8, 2004
Filed:
Mar 21, 2003
Appl. No.:
10/394902
Inventors:
Yin Liang - Bridgewater NJ, US
Jian Zhu - North Haven CT, US
Laurel Sweet - Branford CT, US
James Livingston - Guilford CT, US
Assignee:
Bayer Pharmaceuticals Corporation - West Haven CT
International Classification:
A61K045/00
C12N005/08
US Classification:
424/093700, 435/366000
Abstract:
The present invention relates to a method for preparing pseudo islets. In addition, the invention is also directed to methods of treating diabetes and diabetes-related disorders by administering compounds identified by the methods described herein.

Method Of Use For Substituted Dipiperidine Ccr2 Antagonists

View page
US Patent:
20070219245, Sep 20, 2007
Filed:
Mar 13, 2007
Appl. No.:
11/685247
Inventors:
Cuifen Hou - Spring House PA, US
Yin Liang - Ambler PA, US
Keith T. Demarest - Flemington NJ, US
Druie E. Cavender - Flemington NJ, US
Michael P. Wachter - Bloomsbury NJ, US
Mingde Xia - Belle Mead NJ, US
International Classification:
A61K 31/4545
US Classification:
514316
Abstract:
The present invention is directed to a method for use of substituted dipiperidine compounds of Formula (I)or a salt, isomer, prodrug, metabolite or polymorph thereof, which are CCR2 antagonists, for preventing, treating or ameliorating syndromes, disorders or diseases related to CCR2 activation in a subject in need thereof.

Combination Therapy For The Treatment Of Diabetes

View page
US Patent:
20110009347, Jan 13, 2011
Filed:
Jul 6, 2010
Appl. No.:
12/830479
Inventors:
Yin Liang - Ambler PA, US
John Ryan - Chalfont PA, US
Abraham B. Woldu - Souderton PA, US
Lisa Wu - Merion Station PA, US
International Classification:
A61K 31/7064
A61K 31/7042
A61P 3/10
A61P 43/00
A61P 5/50
A61P 3/00
A61P 3/06
A61P 3/04
A61P 9/10
A61P 9/12
US Classification:
514 23
Abstract:
The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein.

Use Of Alpha-Methylglucoside (Amg) As An Indicator For Glucose Absorption And Excretion

View page
US Patent:
20110065200, Mar 17, 2011
Filed:
Sep 14, 2010
Appl. No.:
12/881695
Inventors:
Keith T. Demarest - Flemington NJ, US
James M. Lenhard - Fort Washington PA, US
Gregory C. Leo - Lansdale PA, US
Yin Liang - Owings Mills MD, US
Tonya L. Martin - Quakertown PA, US
Assignee:
Janssen Pharmaceutica, N.V. - Beerse
International Classification:
G01N 33/50
US Classification:
436 93
Abstract:
Presented here are methods using alpha-methylglucoside (AMG) in vivo as an indicator for glucose absorption from the gastrointestinal (GI) system or glucose excretion in the urine after oral administration of AMG. The methods find use in, for example, but not limited to, determining the effect of a sodium-dependent glucose transporter (SGLT) inhibitor in an animal, comparing the differences in the effects of a first and second SGLT inhibitor in an animal, and diagnosing a disease associated with glucose absorption from the gastrointestinal (GI) system or glucose excretion from the kidney in an animal.

Benzocyclobutane Derivatives Useful As Dual Sglt1 / Sglt2 Modulators

View page
US Patent:
20190367469, Dec 5, 2019
Filed:
Nov 8, 2017
Appl. No.:
16/348304
Inventors:
- Beerse, BE
Guozhang Xu - Chesterbrook PA, US
Yin Liang - Ambler PA, US
Assignee:
Janssen Pharmaceutica NV - Beerse
International Classification:
C07D 309/10
Abstract:
The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.

Wikipedia

Michael & Victor

View page

... du xin); Having You Beside Me () - May 1997 - (Malaysian version CD of Wu Yin Liang Pin X 2); Wu Yin Liang Pin x 2 (x 2; W Yn Ling ...

Control profile
Yin Liang from Alexandria, VA, age ~70 Get Report